Obsessive-Compulsive Disorder (OCD)Set & Setting

Improvement in OCD symptoms associated with serotoninergic psychedelics: a retrospective online survey

In a retrospective online survey of 174 participants, classic serotoninergic psychedelics were the only substances reported to reduce OCD symptoms. Reduction correlated with the intensity of acute effects (itself linked to dose), persisted variably from weeks to months with no clear predictors, and larger/more persistent improvements predicted subsequent intake frequency.

Authors

  • Valerie Bonnelle

Published

Scientific Reports
individual Study

Abstract

A renewed interest in the use of psychedelics for treating obsessive compulsive disorder (OCD) has emerged in the last 20 years. But pre-clinical and clinical evidence remain scarce, and little is known about the factor determining the magnitude and persistence of the therapeutic effect. We therefore designed a retrospective online survey to explore, in the general population using psychoactive drugs, their impact on OCD symptoms. We also assessed the attitude of the participants towards the substance in term of frequency of intakes. In a sample of 174 participants, classic psychedelics were reported as the only substances effective at reducing OCD symptoms. In classic psychedelics users, symptoms reduction was associated with the intensity of acute effects, itself correlated to the dose. Reports on the persistence of the therapeutic effect varied from weeks to months, but we could not find any predicting factor. Finally, the occurrence and frequency of subsequent intakes, which seemed to be limited in our sample, were predicted by the magnitude and persistence of the therapeutic effect, respectively. Our observations support the hypothesis of classic psychedelics efficacy in reducing OCD symptoms but a careful evaluation of the persistence of this effect is still needed.

Available with Blossom Pro

Research Summary of 'Improvement in OCD symptoms associated with serotoninergic psychedelics: a retrospective online survey'

Introduction

OCD is a chronic, often disabling psychiatric disorder featuring intrusive obsessions and repetitive compulsions. Standard treatments combine cognitive and behavioural therapy with high-dose selective serotonin reuptake inhibitors (SSRIs), but many patients have incomplete response, long delays to benefit and 30–40% non-response. This gap has renewed interest in alternative approaches, including classic serotoninergic psychedelics such as LSD and psilocybin, but clinical and preclinical evidence for their efficacy in OCD is limited, long-term outcomes are poorly characterised, and placebo/expectation effects are difficult to rule out in open or uncontrolled work. Buot and colleagues therefore conducted a retrospective, anonymous online survey in people with OCD symptoms to identify which psychoactive substances users perceived as changing their OCD, to examine whether any improvement related to features of the acute subjective experience (intensity, pleasantness), mindset and setting, and to document the occurrence and frequency of subsequent intakes. The survey targeted a broad set of substances and sought to explore determinants of both the magnitude and persistence of any self-reported therapeutic effects in a real-world sample.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Create a free account to open full-text PDFs.

Study Details

  • Study Type
    individual
  • Journal
  • Topics
  • Author
  • APA Citation

    Buot, A., Pallares, C., Oganesyan, A., Dauré, C., Bonnelle, V., Burguière, E., Dos Santos, J. F. A., N’Diaye, K., Ljuslin, M., Smith, P., Verroust, V., Wyplosz, B., Morgiève, M., & Mallet, L. (2023). Improvement in OCD symptoms associated with serotoninergic psychedelics: a retrospective online survey. Scientific Reports, 13(1). https://doi.org/10.1038/s41598-023-39812-0

References (23)

Papers cited by this study that are also in Blossom

Long-term Amelioration of OCD Symptoms in a Patient with Chronic Consumption of Psilocybin-containing Mushrooms

Lugo-Radillo, A., Cortes-Lopez, J. L. · Journal of Psychoactive Drugs (2020)

25 cited
Effects of Schedule I drug laws on neuroscience research and treatment innovation

King, C., Nichols, D. E. · Nature Reviews Neuroscience (2013)

Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes

Agin-Liebes, G. I., Lancelotta, R., Uthaug, M. V. et al. · ACS Pharmacology and Translational Science (2021)

Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences

Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S. et al. · Journal of Psychopharmacology (2016)

Cessation and reduction in alcohol consumption and misuse after psychedelic use

Garcia-Romeu, A., Davis, A. K., Fire Erowid et al. · Journal of Psychopharmacology (2019)

211 cited
An online survey of tobacco smoking cessation associated with naturalistic psychedelic use

Johnson, M. W., Garcia-Romeu, A., Johnson, P. S. et al. · Journal of Psychopharmacology (2017)

117 cited
The association of psychedelic use and opioid use disorders among illicit users in the United States

Pisano, V. D., Putnam, N. P., Kramer, H. M. et al. · Journal of Psychopharmacology (2017)

Constructing drug effects: a history of set and setting

Hartogsohn, I. · Drug Science Policy and Law (2017)

389 cited
Psilocybin - Summary of knowledge and new perspectives

Tylš, F., Páleníček, T., Horacek, J. · European Neuropsychopharmacology (2013)

Show all 23 references
Predicting responses to psychedelics: a prospective study

Haijen, E. C. H. M., Kaelen, M., Roseman, L. et al. · Frontiers in Pharmacology (2018)

339 cited
The behavioral pharmacology of hallucinogens

Fantegrossi, W. E., Murnane, K. S., Reissig, C. J. · Biochemical Pharmacology (2007)

Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens

Halberstadt, A. L., Geyer, M. A. · Neuropharmacology (2011)

Prediction of psilocybin response in healthy volunteers

Studerus, E., Gamma, A., Kometer, M. et al. · PLOS ONE (2012)

Trial of Psilocybin versus Escitalopram for Depression

Carhart-Harris, R. L., Giribaldi, B., Watts, R. et al. · New England Journal of Medicine (2021)

927 cited
Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide in healthy subjects

Dolder, P. C., Schmid, Y., Steuer, A. E. et al. · Clinical Pharmacokinetics (2017)

Psilocybin and obsessive compulsive disorder

Wilcox, C. E. · Journal of Psychoactive Drugs (2014)

Hallucinogens, Serotonin and Obsessive-Compulsive Disorder

Delgado, P. L., Moreno, F. A. · Journal of Psychoactive Drugs (1998)

61 cited
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up

Carhart-Harris, R. L., Bolstridge, &. M., Day, C. M. J. et al. · Psychopharmacology (2017)

Psychedelics promote structural and functional neural plasticity

Ly, C., Greb, A. C., Cameron, L. P. et al. · Cell Reports (2018)

Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors

Vargas, M. V., Dunlap, L. E., Dong, C. et al. · Science (2023)

330 cited

Cited By (4)

Papers in Blossom that reference this study

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.

Improvement in OCD symptoms associated with... — Research Summary & Context | Blossom